The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets for $5 ...
The integration of Bruton tyrosine kinase (BTK) inhibitors into first-line treatment regimens, in combination with immunochemotherapy, constitutes the new standard of care following the recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback